Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
Thrombohemorrhagic complications are a major cause of morbidity and mortality in patients with essential thrombocythemia (ET) and polycythemia vera (PV). The pathogenesis of these complications is not completely clarified. Several studies have described abnormalities of red blood cells and platelets in these patients. However, no studies are available on changes in the polymorphonuclear leukocytes (PMNs), which can play an important role in the activation of the hemostatic system. In patients with ET (n = 37) and PV (n = 34), a series of PMN activation parameters (PMN membrane CD11b and leukocyte alkaline phosphatase [LAP] antigen expression, cellular elastase content, plasma elastase, and myeloperoxidase levels) was evaluated simultaneously with the levels of plasma markers of endothelial damage (thrombomodulin and von Willebrand factor antigen) and hypercoagulation (thrombin-antithrombin complex, prothrombin fragment 1 + 2, and D-dimer). The results show the occurrence of PMN activation in both groups of patients compared with a control group of healthy subjects. An increase in CD11b and LAP expression by PMN membrane was observed, together with a significant increase in cellular elastase content, plasma elastase, and myeloperoxidase levels. In addition, patients had high plasma levels of endothelial and hypercoagulation markers compared with controls. For the first time, these data show that in ET and PV, 2 hematologic conditions that place patients at increased risk for thrombosis, an in vivo leukocyte activation occurs and is associated with laboratory signs of endothelium and coagulation system activation. (Blood. 2000;96:4261-4266)
Falanga
A
A
Hematology Division, Ospedali Riuniti, Bergamo, Italy. annafalanga@yahoo.com
Marchetti
M
M
Evangelista
V
V
Vignoli
A
A
Licini
M
M
Balicco
M
M
Manarini
S
S
Finazzi
G
G
Cerletti
C
C
Barbui
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000032:analysis; D000941:Antigens / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D019272:Leukocyte Elastase / Q000032:analysis; D016177:Macrophage-1 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000502:physiology*; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D009195:Peroxidase / Q000032:analysis; D011087:Polycythemia Vera / Q000097:blood* / Q000473:pathology; D011516:Prothrombin / Q000032:analysis; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000473:pathology; D018180:Thrombomodulin / Q000032:analysis; D014841:von Willebrand Factor / Q000276:immunology
D000941:Antigens; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D016177:Macrophage-1 Antigen; D010446:Peptide Fragments; D018180:Thrombomodulin; C029417:Von Willebrand antigen; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C045879:prothrombin fragment 1.2; D014841:von Willebrand Factor; D000990:Antithrombin III; D011516:Prothrombin; D009195:Peroxidase; D000469:Alkaline Phosphatase; D010447:Peptide Hydrolases; D019272:Leukocyte Elastase